E

    Emergent Biosolutions Inc (EBS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $6.09
    +0.18 (+3.05%)

    Market Cap: $303.02M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -24.92%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.41 - $-0.37
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$0.35+189.4%
    60d ago$0.35+189.4%
    30d ago$0.35+189.4%
    7d ago$-0.41-4.8%
    Current$-0.39
    Revenue Consensus
    $123M
    Range$118M - $129M
    3 analysts
    Dec 31, 2026
    EPS Consensus$0.89
    Range$0.89 - $0.89
    2 analysts
    Revenue Consensus
    $196M
    Range$184M - $205M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.89---
    Sep 26EST
    		-$-0.39---
    Jun 26
    		$0.60$0.11+445.45%Beat+275.0%
    Mar 26
    		$0.21$-0.25+184.00%Beat-70.4%
    Dec 25
    		$-0.43$0.42-201.18%Miss+25.5%
    Sep 25
    		$1.06$-0.12+983.33%Beat-22.6%
    Jun 25
    		$0.16N/A+132.65%Beat+106.9%
    Mar 25
    		$0.71$0.44+61.36%Beat+20.3%
    Dec 24
    		$-0.58$-0.50-16.50%Miss+25.0%
    Sep 24
    		$1.37$0.14+878.57%Beat+127.0%
    Jun 24
    		$-2.32$-0.97-139.18%Miss-118.9%
    Mar 24
    		$0.59$-0.83+171.08%Beat+118.6%
    Dec 23
    		$-0.77$-0.19-305.26%Miss-148.4%
    Sep 23
    		$-5.08$-0.54-840.74%Miss-300.0%
    Jun 23
    		$-1.06$-0.62-70.97%Miss-23.3%
    Mar 23
    		$-3.17$-1.34-136.57%Miss-1861.1%
    Dec 22
    		$-0.31$0.04-875.00%Miss-106.9%
    Sep 22
    		$-1.27$-0.13-876.92%Miss-252.8%
    Jun 22
    		$-0.86$0.40-315.00%Miss-360.6%
    Mar 22
    		$0.18$0.13+38.46%Beat-88.2%
    Dec 21
    		$4.50$4.27+5.39%Beat+22.6%
    Sep 21
    		$-0.36N/A-115.79%Miss-116.4%
    Jun 21
    		$0.33N/A-78.85%Miss-83.3%
    Mar 21
    		$1.53$1.17+30.77%Beat+15200.0%
    Dec 20
    		$3.67$3.19+15.05%Beat+133.8%
    Sep 20
    		$2.19$2.15+1.86%Beat+81.0%
    Jun 20
    		$1.98$0.66+200.00%Beat+1550.0%
    Mar 20
    		$0.01$0.01+0.00%Beat+107.7%
    Dec 19
    		$1.57$1.73-9.25%Miss+109.3%
    Sep 19
    		$1.21$0.90+34.44%Beat+120.0%
    Jun 19
    		$0.12$0.18-33.33%Miss-88.8%
    Mar 19
    		$-0.13$0.18-172.22%Miss-333.3%
    Dec 18
    		$0.75$0.65+15.38%Beat+1.4%
    Sep 18
    		$0.55$0.61-9.84%Miss-24.7%
    Jun 18
    		$1.07$0.93+15.05%Beat+723.1%
    Mar 18
    		$-0.03N/A-117.65%Miss-110.3%
    Dec 17
    		$0.74$0.70+5.71%Beat+0.0%
    Sep 17
    		$0.73$0.41+78.05%Beat+25.9%
    Jun 17
    		$0.13$0.26-50.00%Miss-
    Mar 17
    		$0.29$0.30-3.33%Miss-
    Dec 16
    		$0.74$0.61+21.31%Beat-
    Sep 16
    		$0.58$0.38+52.63%Beat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio4.23EV/EBITDA5.24x
    Price/FCF3.66xFCF Yield27.34%
    Profitability
    Profit Margin-23.00%Operating Margin28.30%
    ROE-40.30%ROIC16.71%
    Financial Health
    Debt/Equity1.70xInterest Coverage2.16x
    Current Ratio5.42xQuick Ratio2.95x
    Trading Statistics
    Beta2.36Avg Volume1.54M
    52-Week High$14.0652-Week Low$4.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.42
    SMA 20$5.32
    SMA 50$6.84
    SMA 200$9.12
    EMA 10$5.61
    EMA 20$5.70
    EMA 50$6.51
    EMA 200$8.07

    MACD

    Line: -0.28Signal: -0.52Hist: 0.24

    ADX

    ADX: 32.7+DI: 27.0-DI: 27.2

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down40.0
    PSAR$4.56

    Bollinger Bands

    Upper Band$7.22
    Lower Band$3.43
    %B Position7103%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    53.6

    Momentum Oscillators

    Stoch %K94.5
    Stoch %D93.3
    Williams %R-1.2
    ROC (10d)35.3%
    Momentum1.59
    CCI (20d)63.1
    MFI (14d)88.3

    Volatility Measures

    ATR (14d)$0.35(5.8%)
    StdDev (20d)0.95
    Hist Vol127.2%(High)

    Volume Flow

    VWAP$6.00
    OBV-32.1M
    AD Line-20.6M
    CMF (20d)-0.003

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio0.7x
    VWMA (20d)$5.11

    Pivot Points

    R3$6.28
    R2$6.20
    R1$6.05
    Pivot Point$5.97
    S1$5.82
    S2$5.74
    S3$5.59

    Advanced Oscillators

    TSI-19.09
    Ultimate Osc74.3
    KST-242.41

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$234.30M$156.10M$148.70M$231.10M$140.90M$222.20M$194.70M$293.80M$254.70M$300.40M$-755,700,000$519.30M
    Cost of Revenue$97.10M$72.00M$84.90M$85.90M$66.90M$88.50M$118.00M$122.60M$296.10M$144.60M$-182,300,000$353.60M
    Gross Profit$137.20M$84.10M$63.80M$145.20M$74.00M$133.70M$76.70M$171.20M$-41,400,000$155.80M$-573,400,000$165.70M
    Operating Expenses$262.30M$73.60M$91.70M$68.70M$72.40M$83.80M$86.20M$106.70M$162.10M$116.00M$-495,500,000$335.80M
    R&D$9.20M$10.50M$12.10M$13.50M$12.50M$15.10M$9.10M$13.80M$32.70M$15.10M$29.40M$15.30M
    SG&A$44.60M$46.60M$51.10M$38.90M$43.70M$52.40M$60.80M$76.60M$85.90M$84.70M$-541,100,000$86.00M
    Operating Income$-125,100,000$10.50M$-27,900,000$76.50M$1.60M$49.90M$-9,500,000$64.50M$-203,500,000$39.80M$-43,800,000$-242,100,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$30.50M$11.00M$26.90M$15.20M$14.70M$14.70M$14.20M$8.30M$23.60M$24.30M$10.70M$23.80M
    Income Before Tax$-166,300,000$13.40M$-50,700,000$57.60M$-16,800,000$92.70M$-27,600,000$142.40M$-269,800,000$12.10M$-54,500,000$-265,900,000
    Income Tax Expense$13.90M$6.60M$3.90M$6.40M$-4,800,000$24.70M$3.70M$27.60M$13.30M$3.10M$-5,000,000$-2,500,000
    Net Income$-180,200,000$6.80M$-54,600,000$51.20M$-12,000,000$68.00M$-31,300,000$114.80M$-283,100,000$9.00M$-49,500,000$-263,400,000
    EBITDA$-110,200,000$49.70M$2.30M$98.70M$23.80M$135.10M$14.80M$170.40M$-212,700,000$71.20M$-42,700,000$-212,500,000
    EBIT$-135,800,000$24.40M$-23,800,000$72.80M$-2,100,000$107.40M$-13,400,000$150.70M$-246,200,000$36.40M$-78,000,000$-246,200,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EBS

    Government Contracts

    Gov Obligations (TTM)
    $277.58M
    Gov Obligations / Revenue
    41.0%
    Obligations YoY
    13.9%
    Active Awards
    11
    New Awards (TTM)
    3
    Avg Remaining Term
    6.6 mo

    Top agency: Department of Health and Human Services at 92.2% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    W911SR26FA005Department of DefenseDepartment of the Army$21.53MJan 4, 2026
    75N98026P00379Department of Health and Human ServicesNational Institutes of Health$11232Apr 27, 2026
    75D30126P20965Department of Health and Human ServicesCenters for Disease Control and Prevention$2825Apr 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Emergent BioSolutions Q1 Net Income USD 6.8 M

    Emergent BioSolutions reported a net income of $6.8 million for the first quarter. This financial update provides key performance indicators for the company during the specified period.

    Moomoo•8/25/26•
    Somewhat-Bullish

    EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Emergent Biosolutions Inc. - EBS

    Kahn Swick & Foti, LLC (KSF) and former Louisiana Attorney General Charles C. Foti, Jr. are reminding investors of Emergent BioSolutions Inc. (NYSE: EBS) with losses over $100,000 of the June 18, 2021 lead plaintiff deadline for securities class action lawsuits. The lawsuits allege that Emergent failed to disclose material information between April 24, 2020, and April 16, 2021, regarding manufacturing issues at its Bayview facility that led to the spoilage of COVID-19 vaccine doses, causing a significant drop in stock price. Investors who purchased shares during this period are encouraged to contact KSF to discuss their legal rights.

    TMX Newsfile•8/25/26•
    Neutral

    Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Connect

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Emergent BioSolutions Inc. (EBS) on behalf of investors. This investigation follows Emergent's announcement of a $191.3 million non-cash impairment charge on its NARCAN asset group and a cut in full-year revenue guidance, leading to a significant drop in its stock price. The law firm is encouraging affected stockholders to connect and assist with the investigation.

    ACCESS Newswire•8/24/26•
    Bearish

    Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Emergent BioSolutions Inc. (EBS) securities. This investigation follows Emergent's August 5, 2026 announcement of a $191.3 million non-cash impairment charge on its NARCAN asset group and a cut in full-year revenue guidance, which led to a significant drop in the company's stock price. The law firm encourages affected investors to contact them to learn more about participating in a potential class action lawsuit.

    ACCESS Newswire•8/23/26•
    Bearish

    JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS)

    JPMorgan Chase & Co. has initiated coverage on Emergent Biosolutions (NYSE:EBS) with an "underweight" rating, joining a mixed analyst outlook for the biopharmaceutical company. Despite the new rating, Emergent Biosolutions saw its stock trade up 2.5% to $4.94. The company's recent quarterly earnings exceeded expectations, but analysts still forecast a full-year loss per share.

    MarketBeat•8/21/26•
    Somewhat-Bearish

    Frequently Asked Questions About EBS

    Does EBS pay dividends?
    Emergent Biosolutions Inc (EBS) has a dividend payment track record. See the EBS dividend history page for its current payment status, yield, and streaks.
    What is EBS's P/E ratio?
    Emergent Biosolutions Inc has a price-to-earnings (P/E) ratio of 4.23.
    What is EBS's market cap?
    Emergent Biosolutions Inc (EBS) has a market capitalization of $303.02M with a current stock price of $6.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In